Wuling San Based on Network Pharmacology and in vivo Evidence Against Hyperuricemia via Improving Oxidative Stress and Inhibiting Inflammation
Jing Huang,Zhijian Lin,Yu Wang,Xueli Ding,Bing Zhang
DOI: https://doi.org/10.2147/DDDT.S398625
2023-03-05
Abstract:Jing Huang, Zhijian Lin, Yu Wang, Xueli Ding, Bing Zhang School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence: Bing Zhang, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China, Email Background: Hyperuricemia (HUA) is a major public health issue with a high prevalence worldwide. Wuling San (WLS) is an effective treatment for HUA. However, the active compounds and the related mechanism are unclear. In this study, we aimed to explore the active compounds and the underlying pharmacological mechanisms of WLS against HUA. Methods: First, a network pharmacology approach was used to detect active compounds of WLS, and potential targets and signaling pathways involved in the treatment of HUA were predicted. Then, a molecular docking strategy was used to predict the affinity between active compounds and key targets. Finally, to verify the prediction, the HUA rat model was established. Results: 49 active compounds with 108 common targets were obtained. Besides, cerevisterol, luteolin, ergosterol peroxide, beta-sitosterol, and sitosterol were identified as key active compounds. In PPI analysis, TNF, IL6, CASP3, PPARG, STAT3, and other 12 core targets were obtained. GO enrichment analysis indicated that WLS was likely to interfere with oxidative stress in the treatment of HUA, and KEGG enrichment analysis indicated multiple inflammation-related signaling pathways possibly involved in the treatment of HUA by WLS, including TNF, and NOD-like receptor, HIF-1, PI3K-Akt, and IL-17 signaling pathways. The results of molecular docking indicated that the active compounds had good binding properties to their key targets. In the validation experiments, WLS significantly reduced the levels of serum uric acid (SUA) and serum malondialdehyde (MDA). Moreover, WLS not only significantly increased the levels of total antioxidant capacity (T-AOC) and superoxide dismutase (SOD), but also inhibited the expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Conclusion: In the present study, we demonstrate that WLS has multicomponent, multitarget, and multi-pathway properties in the treatment of HUA. Its potential capability to reduce SUA could be ascribed to oxidative stress improvement and inflammation inhibition. Keywords: hyperuricemia, Wuling San, oxidative stress, inflammation Hyperuricemia (HUA) is a common metabolic disorder characterized by an abnormally high level of SUA. It results from a reduction in UA excretion or an increase in UA production, or both. In mainland China, the prevalence of HUA in the general population was 17.4% (22.7% in males and 11.0% in females), 1 which became a major public health concern. In addition to the well-known association with gout, increased SUA has been reported to play a critical role in cardiometabolic diseases, including hypertension, 2 atrial fibrillation, 3 chronic kidney disease, 4 type 2 diabetes, 5 obesity, 6 hypertriglyceridemia, 7 metabolic syndrome 8 and non-alcoholic fatty liver disease. 9 Increased UA levels reflect an increase in xanthine oxidase (XO) enzymatic activity, which also results in an increased production of reactive oxygen species (ROS), leading to oxidative stress. 10 Oxidative stress can activate several transcription factors, resulting in differential expression of certain genes involved in inflammation. Furthermore, inflammation caused by oxidative stress is the cause of many chronic diseases. 11 Inflammation and oxidative stress are implicated in the mechanisms underlying HUA-mediated chronic kidney injury, 12 and cardiovascular diseases. 13–15 Uric acid-lowering therapy (ULT) is widely used to treat HUA and prevent gout. The 2020 American College of Rheumatology (ACR) guidelines recommended that the target level of SUA in patients with ULT should be less than 6 mg/dl. 16 At present, the anti-HUA drugs in clinical practice include allopurinol, febuxostat, probenecid, and benzbromarone. However, anti-HUA reagents often cause adverse effects such as allopurinol hypersensitivity reactions, 17 toxic epidermal necrolysis, 18 abnormal liver and kidney function tests, 19 blood dyscrasias, and urolithiasis. 20 There is growing evidence that natural medicines play a significant role in lowering UA. 21–24 Therefore, exploring natural and nontoxic anti-HUA drugs from traditional Chinese medicine or natural compounds has become a research hotspot. WLS (also called Oryeongsan in Korea and Gore-san or TJ-17 in Japan), recognized as a safe medicine since ancient -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal